Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare To Pay For Presbyopia IOLs; Firms Prepare Marketing Blitz

This article was originally published in The Gray Sheet

Executive Summary

Presbyopia intraocular lens manufacturers will now be able to target the more than 2 mil. cataract surgery patients served by Medicare, following CMS' ruling to allow partial payment for the lenses

You may also be interested in...



Eyeonics Eyes International Sales Force Creation With Planned IPO Proceeds

Premium intraocular lens maker Eyeonics will establish a direct sales force outside the United States and expand its domestic sales and marketing activities with the proceeds of a planned initial public stock offering

Eyeonics Eyes International Sales Force Creation With Planned IPO Proceeds

Premium intraocular lens maker Eyeonics will establish a direct sales force outside the United States and expand its domestic sales and marketing activities with the proceeds of a planned initial public stock offering

Refractive IOL Market On Track To Approach $1 Bil. By 2010, AMO Asserts

Advanced Medical Optics projects the worldwide refractive intraocular lens market will reach $180 mil.-$200 mil. this year and approach $1 bil. by 2010, based on accelerating uptake of the technology

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT022117

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel